GlassScriptPhysician profile
Vimal P Amin
NPI 1366464497
$4,349.95
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,991 · 2020: $931 · 2021: $336 · 2022: $64.98 · 2023: $26.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,311.01 | 2019-2020 | |
| Abbvie INC. | $685.03 | 2019-2021 | |
| Janssen Biotech, INC. | $351.64 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.73 | 2019-2020 | |
| Braintree Laboratories, INC. | $121.85 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $112.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.29 | 2019-2020 | |
| Pfizer INC. | $51.46 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.53 | 2022 | |
| Nestle Healthcare Nutrition INC. | $33.57 | 2020-2021 | |
| Ucb, INC. | $30.33 | 2019 | |
| Intercept Pharmaceuticals, INC. | $26.87 | 2023 | Ocaliva |
| Cardiovascular Systems INC. | $26.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.15 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18.65 | 2020 | |
| Redhill Biopharma INC. | $14.18 | 2020 | |
| Shionogi INC | $13.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimal Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.